Skip to main content
Fig. 6 | BMC Medicine

Fig. 6

From: Synthetic high-density lipoprotein nanoparticles for the treatment of Niemann–Pick diseases

Fig. 6

5A-SM removes sphingomyelin from Niemann–Pick type A fibroblasts. a Control (CTRL) and Niemann–Pick A (NPA) primary fibroblasts were incubated with [3H] sphingomyelin for 24 h, followed by treatment with 0.75 mg/ml 5A-SM or vehicle (Veh). Radioactivity in media and cell fractions was determined by liquid scintillation counting. b CTRL and NPA primary fibroblasts were loaded with NBD-sphingomyelin, then treated for 48 h with vehicle (Veh), cyclodextrin (Cyclo), or 0.75 mg/ml 5A-SM. NBD-sphingomyelin intensity quantified at right. Scale bar = 20 μm. c SRS microscopy was used to image total endogenous lipids in CTRL and NPA cells with the indicated treatments. Quantified at right. Scale bar = 20 μm. Data are mean ± s.e.m. from a, b, c three; *p ≤ .05, ***p ≤ .001, ****p ≤ .0001. a Student’s t test (t = 6.04); b, c one-way ANOVA with Tukey post hoc test (F, df = (b) 55.57, 3; (c) 8.285, 3)

Back to article page